CONTINUED STRONG SALES GROWTH AND FDA APPROVAL FOR XPS™ AND STEEN SOLUTION™

THIRD QUARTER 2014 (JUL – SEP)

 • Net sales in the quarter amounted to SEK 22.4 (16.8) million, corresponding to an increase of 34 percent.
• Net sales for consumables in the quarter amounted to SEK 21.0 (16.8) million, corresponding to an increase of 25 percent in SEK. Sales for consumables increased by 18 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.4 (3.8) million, corresponding to an EBITDA margin of 15 percent.
• Net income amounted to SEK 1.5 (1.6) million, resulting in earnings per share of SEK 0.07 (0.08).
• Cash flow from operating activities was SEK 4.3 (-1.5) million.
• Products for warm perfusion (STEEN Solution™ and products related to the use of the XPS™) accounted for 25 (13) percent of total consumables sales.
• The FDA granted marketing approval for XPS™ and STEEN Solution™, allowing STEEN Solution™, XPS™ and the accompanying single-use products to be sold in the US.
• XVIVO Perfusion’s share warrant program 2014/2016, which was offered to employees, was fully subscribed.
• XVIVO Perfusion completed a share issue through a private placement of SEK 73 million.

THE PERIOD 2014 (JAN – SEP)

• Net sales in the period amounted to SEK 59.2 (48.9) million, corresponding to an increase of 21 percent.
• Net sales for consumables in the period amounted to SEK 57.7 (48.9) million, corresponding to an increase of 18 percent in SEK. Sales for consumables increased by 14 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 8.3 (10.0) million, corresponding to an EBITDA margin of 14 percent.
• Net income amounted to SEK 4.1 (5.7) million, resulting in earnings per share of SEK 0.20 (0.29).
• Cash flow from operating activities was SEK 1.7 (6.4) million.
• Products for warm perfusion (STEEN Solution™ and products related to the use of the XPS™) accounted for 24 (14) percent of total consumables sales. XPS™ (Xvivo Perfusion System) received a CE mark, allowing XPS™ and the accompanying single-use products to be sold in Europe.
• The FDA approved marketing approval for XPS™ and STEEN Solution™, allowing STEEN Solution™, XPS™ and the accompanying single-use products to be sold in the US.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, October 24, 2014. Telephone: +44 (0) 2071 928000, enter code 19023328

October 24, 2014
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson
CEO

For further information please contact:

Christoffer Rosenblad, CFO, +46 31 788 21 59, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication on October 24, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Tags: